2016-09761. Office of Medical Products and Tobacco; Center for Drug Evaluation and Research; Statement of Organization, Functions, and Delegations of Authority  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA), Office of Medical Products and Tobacco, Center for Drug Evaluation and Research, Office of Medical Policy has modified its structure. This new organizational structure was approved by the Secretary of Health and Human Services on December 15, 2016, and effective on April 17, 2016.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Melanie Keller, Office of Management, Center for Drug Evaluation and Research, Office of Medical Products and Tobacco, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 301-796-3291.

    I. Summary

    This organization will expand current activities in the Office of Medical Policy and foster efficient oversight of clinical trials conducted through policy initiatives that build quality upfront and science-based inspectional approaches. This will provide an oversight and direction for new and ongoing policy initiatives in broad-based medical and clinical policy areas, including initiatives to improve science and efficiency trials.

    The Food and Drug Administration, Office of Medical Products and Tobacco, Center for Drug Evaluation and Research, Office of Medical Policy has been restructured as follows:

    DKKNF. ORGANIZATION. The Office of Medical Policy is headed by the Director, Office of Medical Policy and includes the following organizational units:

    Office of Medical Policy

    Office of Prescription Drug Promotion

    Division of Advertising and Promotion Review I

    Division of Advertising and Promotion Review II

    II. Delegations of Authority

    Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.

    III. Electronic Access

    This reorganization is reflected in FDA's Staff Manual Guides (SMG). Persons interested in seeing the complete Staff Manual Guide can find it on FDA's Web site at: http://www.fda.gov/​AboutFDA/​ReportsManualsForms/​StaffManualGuides/​default.htm.

    Start Authority

    Authority: 44 U.S.C. 3101.

    End Authority Start Signature

    Dated: April 19, 2016.

    Sylvia M. Burwell,

    Secretary of Health and Human Services.

    End Signature End Further Info End Preamble

    [FR Doc. 2016-09761 Filed 4-26-16; 8:45 am]

    BILLING CODE P

Document Information

Published:
04/27/2016
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2016-09761
Pages:
24822-24822 (1 pages)
PDF File:
2016-09761.pdf